Trifanucla (Ningbo) Medical Technology

Trifanucla (Ningbo) Medical Technology, also known as Astathera, was founded in November 2020 by CEO Dr. Yutian Feng, along with co-founders Weibin Zhuo and Tongjiang Cui. The company focuses on developing and producing medical radioisotopes and radiopharmaceuticals for cancer treatment, specializing in Targeted Alpha Therapy (TAT).

Headquartered in Ningbo, China, Trifanucla is building a production base in Haiyan, which is expected to begin commercial supply of new medical isotopes, including astatine-211 (At-211), in the second half of 2025. This facility will house two 30MeV cyclotrons, one of which is a high-current alpha accelerator developed with ACSI, designed to produce alpha nuclides. The company's core technical team includes talent from institutions such as Duke University and the University of Missouri. Dr. Michael Zalutsky, a prominent researcher in At-211 production and applications from Duke University, serves as a chief advisor.

As a contract research organization (CRO), Trifanucla offers a one-stop service for global pharmaceutical companies, covering the entire preclinical radiopharmaceutical development process from isotope supply and labeling to in-vivo evaluation in small animals. The business model centers on providing these CRO services and, upon operational commencement of its production facility, the commercial supply of radioisotopes like At-211. Targeted Alpha Therapy uses alpha-emitting radionuclides that deliver high-energy, short-range radiation to selectively destroy cancer cells while minimizing damage to nearby healthy tissue. At-211 is considered a promising isotope for TAT due to its 7.2-hour half-life and potent cell-killing capabilities.

Trifanucla has secured several funding rounds, including a Pre-A round in July 2022 and a strategic financing round in May 2024 to support its production ramp-up. The company is a founding member and the sole Chinese representative of the World Astatine Community, a European nuclear medicine technology cooperation organization.

Keywords: Astatine-211, Targeted Alpha Therapy, radiopharmaceuticals, medical isotopes, nuclear medicine, CRO services, cancer treatment, theranostics, radionuclide production, cyclotron, preclinical research, oncology, isotope labeling, At-211, alpha emitters, Yutian Feng, radioisotope development, molecular radiotherapy, cancer therapy, radiation oncology